AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...
Symptoms typically begin with constipation and sleep problems, up to 20 years before progressing into dementia and the ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form of slowness, rigidity, and tremors.
Environmental factors like prolonged stress, chronic inflammation and toxic exposure could play a key role in triggering ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.